Best Testicular cancer Doctors Worldwide — TOP 116

33 years specializing in cancer immunotherapy and targeted therapies for testicular cancer at Anadolu Medical Center – Prof. Karagöz combines deep research with clinical practice.

• Professor at Istanbul Okan University – trains upcoming oncologists
• Published 40+ research papers in cancer treatment
• Former head of medical oncology at GATA Haydarpaşa Training Hospital
• Specializes in tumor biology and immunology-based approaches

Dr. Zafer Gulbas founded and directs Turkey’s largest Bone Marrow Transplant Center at Anadolu Medical Center. He is a hematologist-oncologist specializing in complex blood cancers and clotting disorders. Dr. Gulbas trained at top global institutions, including MD Anderson and Fred Hutchinson in the USA. He performs autologous and allogeneic transplants for leukemia, lymphoma, and aplastic anemia.

• Achieved an 81% success rate for autologous bone marrow transplants.
• Supervised over 3,000 successful transplant procedures since 2010.
• Authored over 260 scientific publications with 5,000+ citations in hematology.
• Member of the European Hematology Association and American Hematology Association.

Dr. Ilker Tinay is an urological oncologist at Anadolu Medical Center. He sits on the Executive Board of the Association of Urooncology. Dr. Tinay specializes in minimally invasive surgery and neo-bladder reconstruction. He works at Anadolu, a Top 10 global hospital according to MTQUA. The center is also affiliated with Johns Hopkins Medicine.

• Member of the American College of Surgeons and European Association of Urology.
• Secretary of the Bladder Tumours Research Group.
• Winner of the Urooncology Association Scientific Research Award.
• Performs complex procedures including robotic da Vinci prostatectomy and nephrectomy.

Dr. Banu Atalar is a professor and radiation oncologist at Anadolu Medical Center. She is an Honorary Fellow of the American College of Radiology (H.FACR). She completed a clinical research fellowship in stereotactic radiosurgery at Stanford University. Stereotactic radiosurgery and MR-guided adaptive SRS make up 75% of her clinical practice.

• President of the Turkish Society for Radiation Oncology.
• Chair of the ESTRO National Societies Committee.
• Recipient of the ASCO International Development and Education Award.
• Author of over 70 international peer-reviewed publications.

Dr. Huseyin Baloglu is a pathologist at Anadolu Medical Center in Turkey. He leads liquid biopsy and precision oncology services. Dr. Baloglu holds a patent for molecular diagnostics in thyroid cancer treatment. He completed training at Albert Einstein College of Medicine and Heidelberg University.

• Authored over 600 peer-reviewed publications in molecular and surgical pathology.
• Specializes in tumor biopsy, immunohistochemistry, and genetic mutation testing.
• Treats complex oncological cases, including glioblastoma and rare sarcomas.
• Works at Anadolu Medical Center, a facility affiliated with Johns Hopkins Medicine.

Prof. Merimsky leads the Unit of Soft Tissue and Bone Oncology at Sourasky Medical Center with specialized focus on rare cancers.

• 41 years dedicated to sarcoma and rare tumor oncology
• Fellowship-trained at Institut Gustave Roussy – Europe's leading sarcoma center
• Member of ESMO's sarcoma faculty and international research groups
• Published extensively on novel sarcoma treatments

Dr. Sarid leads the oncology, urology, and radiotherapy department at Ichilov Medical Center, bringing extensive expertise in testicular cancer treatment.

• Specialized in cancer urology at Oxford University
• Principal investigator of clinical trials in cancer therapies
• Published over 30 articles on cancer treatment
• Member of European and American oncology societies

Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.

Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.

Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Dr. Stephanie Lilianne E. Bolle is a radiation oncologist and Head of Radiation Oncology at the Quirónsalud Proton Therapy Center in Madrid. She has led the department since July 2024. The center is Spain’s first proton therapy facility.

MD, University of Liège (1998). Board certified in radiation oncology (2003). She is an active member of the European Society of Paediatric Oncology and works with its Brain Tumor Group and Radiation Oncology Working Group.

She has published more than 120 scientific articles on pediatric brain tumors, proton therapy, pediatric radiation doses, and complex radiotherapy. She takes part in international projects and clinical trials, including BIOMEDE 2 and HARMONIC. Her expertise includes proton therapy, pediatric oncology, CNS and skull base tumors in adults and children, sarcomas, and complex radiotherapy planning.

Specializes in integrative therapies for cancer patients, including mistletoe therapy and high-dose vitamin C treatment.

• Oncologist-mammologist treating various breast and hormonal conditions
• Expert in managing chemotherapy and radiation therapy side effects
• Uses natural pain relief methods for cancer patients
• Participant in international medical conferences in Germany and Turkey

Professor Sezer Sağlam specializes in testicular cancer treatment at Gayrettepe Florence Nightingale Hospital, combining decades of oncology expertise with a focus on patient-centered care.

• Professor of Medical Oncology with extensive academic and clinical background
• Member of ESMO, ASCO, and European Neuroendocrine Tumour Society
• Trained at Istanbul University, one of Turkey's leading medical institutions
• Previously served at Istanbul University Oncology Institute in Gastrointestinal Oncology

Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.

He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.

Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.

He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

Professor Doctor Sefik Igdem specializes in Radiation Oncology with advanced technologies like Truebeam Stx and Halcyons at Gayrettepe Florence Nightingale Hospital.

• Over 30 years of experience in radiation oncology
• Expertise in head and neck cancers
• Associate Professor at Demiroğlu Bilim University
• Specializes in conformal treatments for precise radiation therapy

Dr. Amit Tirosh is the Head of the Neuroendocrine Tumors (NET) Service at Sheba Medical Center. He is an international authority on von Hippel–Lindau (VHL) disease and hereditary tumor syndromes. Dr. Tirosh contributed to global clinical guidelines for VHL management. He also leads the Endocrine Oncology Bioinformatics Lab at Sheba.

• Contributor to the international expert panel on VHL management guidelines.
• Authored over 40 peer-reviewed papers in journals like JAMA and Gastroentrology.
• Maintains research affiliations with the NIH and the Weizmann Institute.
• Performs specialized NET treatments, including Lutetium-177 therapy and PRRT.

Dr. Osama Abdel Mohimen Mohamed leads the Hematology Unit at Shefaa Al Orman Oncology Hospital. He treats complex blood cancers, including leukemia, lymphoma, and myeloma. Dr. Mohamed is a member of the European Society for Medical Oncology. He also holds memberships in the American Society of Hematology and ASBMT.

• Specializes in chemotherapy, immunotherapy, and bone marrow transplantation.
• Manages aggressive acute leukemia and chronic blood disorders.
• Treats complications arising from various solid tumors.
• Works at an ESMO-accredited center that handles 6,000 patients annually.

38 years specializing in urologic oncology – Dr. Alcaraz has performed 500+ surgeries for urogenital cancers, including minimally invasive techniques.

• Expert in robotic-assisted surgery using the Da Vinci system
• Specializes in prostate cancer and testicular cancer treatment
• Head of Urology at Teknon Medical Center in Barcelona
• Member of European Urological Society and American Urological Association

Dr. Yuri Goldes is the Deputy Director of General Surgery at Sheba Medical Center. He pioneered some of Israel’s first robotic resections for stomach and pancreatic cancers. Forbes Israel named him among the nation’s best gastrointestinal surgeons. In 2019, he received the Best Doctor of the Year award from the Israeli Ministry of Health.

• Specializes in robotic and laparoscopic surgery for pancreatic, gastric, and esophageal cancers.
• Performs minimally invasive Whipple procedures, one of the most complex abdominal operations.
• Treats benign conditions including diaphragmatic hernia, achalasia, GERD, and gallbladder disease.
• Works at Sheba Medical Center, ranked among the Top 10 hospitals worldwide by Newsweek.

Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).

He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.

Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.

Dr. Sinan Karaaslan is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in treating breast, colorectal, and urogenital system cancers. Dr. Karaaslan brings clinical expertise from major institutions, including Medical Park and Gülhane Military Medical Academy. He works at a hospital affiliated with the Johns Hopkins Hospital.

• Holds personal certification from the European Society for Medical Oncology.
• Treats complex conditions, including stage 4 colon and lung cancers.
• Member of the Turkish Medical Oncology and Turkish Lung Cancer societies.
• Performs systemic therapies such as immunotherapy, targeted therapy, and chemotherapy.